Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA

International Journal of Laboratory Hematology

Volumn 32, Issue 6 PART 1, 2010, Pages

  Bartley, P A ^a   Ross, D M ^a,b   Latham, S ^a   Martin Harris, M H ^a   Budgen, B ^a   Wilczek, V ^a   Branford, S ^b   Hughes, T P ^b   Morley, A A ^a,c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c Monoquant P/L   (Australia)

Author keywords

BCR ABL; chronic myeloid leukaemia; Minimal residual disease; monitoring; PCR

Indexed keywords

BCR ABL PROTEIN; DNA; IMATINIB;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA ISOLATION; DNA SEQUENCE; HUMAN; INTERMETHOD COMPARISON; MINIMAL RESIDUAL DISEASE; NESTED DNA QUANTITATIVE POLYMERASE CHAIN REACTION; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 78349298242     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01236.x     Document Type: Article

References (16)

1. Bartley P.A., Martin-Harris M.H., Budgen B.J., Ross D.M., &, Morley A.A., (2010) Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. British Journal of Haematology, 149, 231 - 236.
2. Bose S., Deininger M., Gora-Tybor J., Goldman J.M., &, Melo J.V., (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood, 92, 3362 - 3367.
3. Branford S., Hughes T.P., &, Rudzki Z., (1999) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology, 107, 587 - 599.
4. Branford S., Rudzki Z., Parkinson I., Grigg A., Taylor K., Seymour J.F., Durrant S., Browett P., Schwarer A.P., Arthur C., Catalano J., Leahy M.F., Filshie R., Bradstock K., Herrmann R., Joske D., Lynch K., &, Hughes T., (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 104, 2926 - 2932.
5. Branford S., Seymour J.F., Grigg A., Arthur C., Rudzki Z., Lynch K., &, Hughes T., (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research, 13, 7080 - 7085.
6. Branford S., Fletcher L., Cross N.C., Muller M.C., Hochhaus A., Kim D.W., Radich J.P., Saglio G., Pane F., Kamel-Reid S., Wang Y.L., Press R.D., Lynch K., Rudzki Z., Goldman J.M., &, Hughes T., (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 112, 3330 - 3338.
7. Gabert J., Beillard E., Van Velden Der V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cave H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., Gonzalez M., Viehmann S., Malec M., Saglio G., &, Van Dongen J.J., (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318 - 2357.
8. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., Van Hoomissen I.C., Goldman J.M., Radich J.P., & Study International Randomised of Interferon Versus S. T. I. S. G. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349, 1423 - 1432. (Pubitemid 37211057)
9. Mattarucchi E., Guerini V., Rambaldi A., Campiotti L., Venco A., Pasquali F., Lo Curto F., &, Porta G., (2008) Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes, Chromosomes and Cancer, 47, 625 - 632.
10. Morley A.A., Latham S., Brisco M.J., Sykes P.J., Sutton R., Hughes E., Wilczek V., Budgen B., Van Zanten K., Kuss B.J., Venn N.C., Norris M.D., Crock C., Storey C., Revesz T., &, Waters K., (2009) Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. Journal of Molecular Diagnostics, 11, 201 - 210.
11. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J., &, Investigators I., (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348, 994 - 1004. (Pubitemid 36302244)
12. Ross D.M., Branford S., Moore S., &, Hughes T.P., (2006) Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia, 20, 664 - 670.
13. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., Blanchet O., Marit G., Gluckman E., Reiffers J., Gardembas M., &, Mahon F.X., (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109, 58 - 60.
14. Waller C.F., Dennebaum G., Feldmann C., &, Lange W., (1999) Long-template DNA polymerase chain reaction for the detection of the bcr/abl translocation in patients with chronic myelogenous leukemia. Clinical Cancer Research, 5, 4146 - 4151.
15. Zhang J.G., Goldman J.M., &, Cross N.C., (1995) Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. British Journal of Haematology, 90, 138 - 146.
16. Zhang J.G., Lin F., Goldman J.M., &, Cross N.C., (1996) Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood, 87, 2588 - 2593.